It is essential for the three monoclonal antibodies for CD44, CD24, and ESA to bind to only PaCSCs. Although these antigens are overabundant in PaCSCs, variants may also be expressed in healthy pancreatic cells. As a result, the liposomes will be engineered so the antibodies will only bind to CD44, CD24, and ESA when these antigens are present in high enough concentrations. Titration assays can determine significant thresholds for these effective antigen concentrations. The liposomes will be administered weekly via intravenous infusion in an aqueous or hydrophilic solution to the patient due to their polar exteriors. Dosage efficiency can be evaluated through repeated titrations for a standardized therapeutic threshold of 95% or greater based on liposomal binding and delivery of contents. After approximately five rounds of treatment, 99.99% of PaCSCs should be eliminated, allowing for a relatively short duration of stem cell therapy.
Recent comments